Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

65.03
+0.36500.56%
Volume:249.79K
Turnover:16.33M
Market Cap:12.57B
PE:171.59
High:66.30
Open:65.92
Low:64.33
Close:64.67
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:2.82
T/O Rate:0.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.99
PE(LYR):36.13

Loading ...

BioMarin’s Voxzogo meets endpoint in Phase 3 pediatric hypochondroplasia trial

TIPRANKS
·
May 21

BioMarin plans FDA filing in Q3 2026 for Voxzogo in hypochondroplasia

Reuters
·
May 21

Biomarin Pharmaceutical Inc: Safety Findings Consistent With Established Profile in Achondroplasia

THOMSON REUTERS
·
May 21

Biomarin Pharmaceutical Inc - No New Safety Signals Identified in Phase 3 Study

THOMSON REUTERS
·
May 21

Biomarin Pharmaceutical Inc - Phase 3 Study Shows 2.33 Cm/Yr Increase in Annualized Growth Velocity at Week 52

THOMSON REUTERS
·
May 21

Biomarin Announces Positive Phase 3 Pivotal Study Results for Voxzogo® (Vosoritide) in Children With Hypochondroplasia

THOMSON REUTERS
·
May 21

Biomarin Pharmaceutical Inc - Plans FDA Supplemental Nda Submission for Voxzogo in Q3 2026

THOMSON REUTERS
·
May 21

U.S. RESEARCH ROUNDUP-CAVA Group, Eagle Materials, Vertiv

Reuters
·
May 20

Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (INFU) and BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
May 20

BioMarin Pharmaceutical Is Maintained at Buy by B of A Securities

Dow Jones
·
May 20

BioMarin price target lowered to $80 from $85 at BofA

TIPRANKS
·
May 19

U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology

Reuters
·
May 19

Assessing BioMarin Pharmaceutical (BMRN) Valuation After Prolonged Share Price Weakness

Simply Wall St.
·
May 19

BioMarin initiated with a Buy at Citi

TIPRANKS
·
May 19

BioMarin Pharmaceutical Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
May 18

Analysts’ Opinions Are Mixed on These Healthcare Stocks: HealthStream (HSTM) and BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
May 18

BUZZ-BioMarin falls after genetic disease therapy shows mixed results in study

Reuters
·
May 18

BioMarin price target lowered to $50 from $55 at H.C. Wainwright

TIPRANKS
·
May 18

Biomarin Pharmaceutical Inc. : H.c. Wainwright Cuts Target Price to $50 From $55

THOMSON REUTERS
·
May 18

BioMarin Pharmaceutical Reports No Functional Improvement in BMN 401 ENPP1 Deficiency Study

MT Newswires Live
·
May 18